Perrigo Company plc Selling Expense
Perrigo Company plc (PRGO) reported Selling Expense of $13.90 million for the 3-month period ending 2014-03-29, per its 10-Q filed 2014-05-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingExpense · last filed 2014-05-07
- Perrigo Company plc selling expense for the quarter ending 2014-03-29 was $13.90M, a 10.32% increase year-over-year.
- Perrigo Company plc selling expense for the quarter ending 2013-12-28 was $14.00M, a 19.66% increase year-over-year.
- Perrigo Company plc selling expense for the quarter ending 2013-03-30 was $12.60M.
- Perrigo Company plc selling expense for the quarter ending 2012-12-29 was $11.70M.
| Period end | Selling Expense 3 month | Selling Expense 6 month | Selling Expense 9 month |
|---|---|---|---|
| 2014-03-29 | $13.90M 10-Q · filed 2014-05-07 | $27.90M derived: sum of 2 quarters · filed 2014-05-07 | $41.20M 10-Q · filed 2014-05-07 |
| 2013-12-28 | $14.00M 10-Q · filed 2014-02-06 | $27.20M 10-Q · filed 2014-02-06 | |
| 2013-03-30 | $12.60M 10-Q · filed 2014-05-07 | $24.30M derived: sum of 2 quarters · filed 2014-05-07 | $35.00M 10-Q · filed 2014-05-07 |
| 2012-12-29 | $11.70M 10-Q · filed 2014-02-06 | $22.50M 10-Q · filed 2014-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |